DGNOF (Diagnos) Ending Cash Position: $0.23 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DGNOF Diagnos Inc DGNOF
22 GF Score
Price $0.28
! 6 Warning Signs
View Full Analysis

What is Diagnos Ending Cash Position?

Diagnos DGNOF -3.82% 22 Ending Cash Position is $0.23 Mil as of Mar. 2026. GuruFocus rates DGNOF with a GF Score™ of 22/100. The stock has 6 warning signs investors should review.

Diagnos's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.23 Mil.

Diagnos's quarterly Ending Cash Position declined from Sep. 2025 ($0.36 Mil) to Dec. 2025 ($0.29 Mil) and declined from Dec. 2025 ($0.29 Mil) to Mar. 2026 ($0.23 Mil).

Diagnos's annual Ending Cash Position declined from Mar. 2024 ($0.16 Mil) to Mar. 2025 ($0.06 Mil) but then increased from Mar. 2025 ($0.06 Mil) to Mar. 2026 ($0.23 Mil).

Diagnos Ending Cash Position Related Terms

Diagnos Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Diagnos's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnos Ending Cash Position Chart

Diagnos Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.22 0.16 0.06 0.23

Diagnos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.09 0.36 0.29 0.23
DGNOF
22GF Score
Diagnos Inc DGNOF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnos Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Diagnos's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.065+0.161
=0.23

Diagnos's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.289+-0.063
=0.23

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.23 Mil mean?
Diagnos (DGNOF) has a Ending Cash Position of $0.23 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Diagnos and its competitors.
Is Diagnos' Ending Cash Position too high?
Diagnos' current Ending Cash Position is $0.23 Mil. Overall, Diagnos has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Diagnos' Ending Cash Position compare to VEEV and BTSG?
Diagnos' Ending Cash Position of $0.23 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Diagnos and its competitors. Diagnos's current Ending Cash Position is $0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Diagnos (DGNOF) has a current Ending Cash Position of $0.23 Mil. The current Ending Cash Position is $0.23 Mil. Diagnos' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Diagnos (DGNOF), the current Ending Cash Position is $0.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diagnos Business Description

Other Exchanges ADK:Canada
Address 7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
22GF Score

Get the complete analysis for DGNOF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price